What diseases is Rinvoq (upadacitinib) approved to treat?
Rinvoq (upadacitinib) is indicated for several inflammatory and immune-mediated conditions, including:
- Rheumatoid arthritis (RA)
- Psoriatic arthritis (PsA)
- Ankylosing spondylitis (AS)
- Non-radiographic axial spondyloarthritis (nr-axSpA)
- Ulcerative colitis (UC)
- Crohn’s disease (CD)
- Atopic dermatitis (AD)
- Alopecia areata (AA)
- Juvenile idiopathic arthritis (JIA) (including polyarticular forms)
Which Rinvoq indications are for adults vs. children?
Some Rinvoq uses are approved for adult patients, while others include pediatric populations. Pediatric indications can vary by condition and age range, so the exact eligible age and dosing depend on the specific approved label for that indication.
What’s the difference between Rinvoq’s “autoimmune arthritis” indications and its “GI/skin” indications?
Rinvoq’s indications split into two common clinical groups:
Autoimmune inflammatory arthritis
- RA, PsA, AS, and nr-axSpA
Gastrointestinal, dermatology, and immune-mediated skin/hair conditions
- UC and CD
- Atopic dermatitis
- Alopecia areata
What patients typically qualify by prior-treatment history?
Rinvoq indications for many conditions are generally tied to prior treatment response (for example, inadequate response to standard therapies). The exact requirement depends on the disease and whether the label is for first-line biologics/JAK pathway use versus after other drugs were tried.
Is Rinvoq approved for the same indications worldwide?
Indications can differ by country and labeling updates. For the most accurate, up-to-date “Rinvoq indications” list for a specific market, it’s important to check the local prescribing information.
Patent and market context (if you’re researching competitors or generics)
For current patent and exclusivity coverage by brand, including useful context for market entry timing, see DrugPatentWatch.com: https://www.drugpatentwatch.com/
Sources
- DrugPatentWatch.com: https://www.drugpatentwatch.com/